AP Biosciences Inc. (6945)

Overview

AP Biosciences Inc is a distinguished clinical-stage biopharmaceutical company dedicated to the research and development of innovative bispecific antibody drugs aimed at addressing unmet medical needs. Established in 2013 and headquartered in Taipei City, Taiwan, the company has swiftly become a notable entity in the field of biopharmaceuticals. Its primary focus lies in developing cutting-edge treatments for a variety of diseases, with a significant emphasis on cancers and age-related conditions. Through its robust research and development program, AP Biosciences Inc has embarked on a mission to advance the science of biopharmaceuticals and bring transformative therapeutic solutions to patients worldwide.

Products and Services

• IBI302 - Currently in phase III clinical trials, IBI302 is a groundbreaking treatment developed for neovascular age-related macular degeneration. This condition significantly impairs vision among the elderly, and IBI302 represents a beacon of hope for those affected, targeting the disease with precision and offering the potential to vastly improve quality of life for patients.
• AP505 - AP505, in the phase I clinical trial stage, is a novel therapeutic solution designed for the treatment of solid tumors. The development of AP505 underscores AP Biosciences' commitment to combating cancer and highlights the company's expertise in harnessing the power of bispecific antibodies to target cancer cells effectively.
• AP203 - Another significant endeavor by AP Biosciences, AP203 is undergoing phase I clinical trials for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas. These types of cancers present formidable challenges, and AP203's development signals a significant advancement in the fight against these deadly diseases.
• AP402 - In the pre-clinical research phase, AP402 is primarily focused on breast cancer patients. The development of this drug exemplifies the company's initiative to expand its research and solutions to encompass a wide array of cancers, aiming to provide targeted and effective treatments for patients suffering from breast cancer.
• AP601 - Also in the pre-clinical research phase, AP601 is being developed to treat lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. This versatile treatment option signifies AP Biosciences' diversified approach to tackling different types of cancers, utilizing its expertise in biopharmaceuticals to develop novel therapies that can potentially save lives and improve patient outcomes.